Authors
Howell, Sacha JAffiliation
The University of Manchester, Institute of Cancer Studies, Manchester, UK.Issue Date
2013-02
Metadata
Show full item recordAbstract
Recent advances in the genomic analysis of breast cancers show promise in better defining endocrine sensitive subtypes. In addition, several key trials have recently reported results that better define the optimal sequence of endocrine agents and approaches to overcome endocrine resistance.Citation
Advances in the treatment of luminal breast cancer. 2013, 25 (1):49-54 Curr Opin Obstet GynecolJournal
Current Opinion in Obstetrics & GynecologyDOI
10.1097/GCO.0b013e32835c0410PubMed ID
23299092Type
ArticleLanguage
enISSN
1473-656Xae974a485f413a2113503eed53cd6c53
10.1097/GCO.0b013e32835c0410
Scopus Count
Collections
Related articles
- A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.
- Authors: Cardoso F, Bischoff J, Brain E, Zotano ÁG, Lück HJ, Tjan-Heijnen VC, Tanner M, Aapro M
- Issue date: 2013 Aug
- Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
- Authors: Zardavas D, Fumagalli D, Loi S
- Issue date: 2012 Nov
- Role of fulvestrant in the management of postmenopausal breast cancer.
- Authors: Krell J, Januszewski A, Yan K, Palmieri C
- Issue date: 2011 Nov
- Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?
- Authors: Safra T, Greenberg J, Ron IG, Ben-Yosef R, Inbar M, Sarid D, Yaal-Hahoshen N
- Issue date: 2008 May
- Fulvestrant ('Faslodex'): current and future role in breast cancer management.
- Authors: Howell A
- Issue date: 2006 Mar